Bellerophon Therapeutics: Q3 Earnings Snapshot
Bellerophon Therapeutics: Q1 Earnings Snapshot
Bellerophon Therapeutics: Q3 Earnings Snapshot
WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...
WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...
WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...
WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...
Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; Company intends to design multi-dose Phase 2b trial Treatment...
WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Monday reported a loss of $4.6 million in its third quarter.
WARREN, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...